EXHIBIT 10.9
*CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN
REQUESTED WITH RESPECT TO THE OMITTED PORTIONS
Memorandum of Understanding
Supply and Services Agreement for SPT1073
Summary
-------
ScinoPharm Taiwan (SPT) will provide API development and manufacturing
functions for ****1073 API to Corcept. This will include Non-GMP, as
well as CGMP products for pre-clinical, clinical and commercial
requirements. ****1073 will be studied by Corcept for treating patients
with psychiatric and cognitive disorders only. In addition, ScinoPharm
Taiwan is willing to act as a consultant to introduce Corcept to
reputable dosage form manufacturers in Taiwan for formulation
development and manufacturing.
Project Plan
------------
1. ScinoPharm and Corcept will jointly invest in the acquisition of
starting materials, equipment and manpower to complete the technology
transfer, process development and scale-up studies. The target date to
deliver total of **** Non-GMP materials for the planned toxicology
study will be August/September, 2000, with smaller quantities (****)
possibly available in July/August.
2. Produce **** of CGMP material by year-end of 2000 for clinical studies.
3. Prepare and submit DMF including all processing and analytical
information for product registration.
4. Introduce Corcept CMC representative(s) to Taiwan dosage form
manufacturers and assist in selecting and establishing a direct working
relationship between Corcept and the selected manufacturer.
Development Out of Pocket Cost
------------------------------
Starting material/reagents etc. ****
Equipment & other supplies ****
**** Manpower **** ****
---------------------------------------------------------
Total **** (1)
(1) At **** shared costs, Corcept will pay $150,000
Product Costs
-------------
Non-GMP Materials ****
GMP Materials ****
**** Reduction to be negotiated.
Quantities
----------
1. Corcept will guarantee minimum purchase of 1 million dollars per year
following product launch.
2. **** 1073 volume purchase in calendar year 2001 could be in the range
of ****
3. **** 1073 purchase forecast, commencing calendar year 2003, will be
between **** annual requirements.
ScinoPharm Taiwan, Ltd. Corcept Inc.
By /s/ Xx Xxxx By Xxxxxx Xxxxxxxx
Title President Title CEO
Date June 1, 2000 Date June 8, 2000
Xxxxxx Xxxxxx
By /s/ Xxxxxx Xxxxxxx
Title President
Date June 12, 2000
2
